Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • PMN310 | Amyloid-Beta
    • PMN267 | TDP-43
    • PMN442 | Alpha-Synuclein
    • Vaccines
    • Posters & Publications
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Results
  • Stock Data
    • NASDAQ: PMN
    • Analyst Coverage
  • SEDAR
  • SEC Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Oct 23, 2020

ProMIS Neurosciences Announces Up to $3 Million Private Placement Offering of Special Warrants

Oct 21, 2020

ProMIS Neurosciences Offers its Perspective on the Likelihood of Regulatory Approval of Aducanumab

Oct 13, 2020

ProMIS Neurosciences’ Neil Cashman to Speak at Protein Misfolding Drug Discovery Conference

Sep 22, 2020

ProMIS Neurosciences to develop multivalent vaccine for Alzheimer’s disease

Sep 10, 2020

ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 22nd Annual Investment Conference

Aug 13, 2020

ProMIS Neurosciences Announces Second Quarter 2020 Results

Jul 29, 2020

ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders

Jul 9, 2020

ProMIS Neurosciences and BC Neuroimmunology announce revenue-sharing joint venture agreement to develop and offer blood-based diagnostic tests for Alzheimer’s disease

Jun 24, 2020

ProMIS Neurosciences announces adjournment and change of location of annual meeting of shareholders

Jun 17, 2020

ProMIS Neurosciences and collaborator BC Neuroimmunology announce significant progress on development of highly accurate antibody test for COVID-19

  • arrow_back
  • 1…
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • …25
  • arrow_forward
  • Email Alerts
  • Contacts
Facebook Linkedin Spotify Twitter
©2025 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy